Addex H1 FY26 net loss widens 4.29% to CHF 3.46 million; operating loss narrows 15.98% to CHF 1.13 million

(AWP Alliance News) - Addex Therapeutics reported a net loss of CHF 3.46 million for H1 2026, widening 4.29% from a loss of CHF 3.31 million a year earlier, while basic and diluted loss per share held at CHF 0.03. Operating loss narrowed 15.98% to CHF 1.13 million, while income slid 83.18% to CHF 18,000. Cash and cash equivalents fell to CHF 767,000 as of June 30, down from CHF 2.3 million a year earlier. Post balance sheet, the group sold 52,970,533 shares for gross proceeds of CHF 2.3 million (USD 2.8 million) under its ATM facility.

The company said it regained rights to its GABAB positive allosteric modulator portfolio from Indivior and is advancing its GABAB PAM chronic cough candidate through preclinical development, while spin-out Neurosterix is on track to complete a Phase 1 study of NTX-253 in Q4 2026.

http://www.globenewswire.com/newsroom/news.html?d=1001274819

Disclaimer: This news brief was created using generative artificial intelligence. Addex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire on September 28, 2026, and is solely responsible for the information contained therein.